Registered title, quoted from ClinicalTrials.gov
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
An open trial on neuromyelitis optica spectrum disorder, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06620809, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 65 years; sex: all
Registered eligibility fields
The Expanded Disability Status Scale (EDSS) score prior to the current disease episode is ≤ 4.
Inclusion criterion 4
Female participants of childbearing potential must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.
Inclusion criterion 5
Pregnant or breastfeeding women, and patients with plans to conceive during the trial.
Exclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06620809, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients must meet the 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD) and test positive for AQP4 antibodies.
- Symptom onset occurred within 7 days prior to enrollment, with associated severe pain, lower limb motor dysfunction, or urinary/bowel impairment.
- Males or Females aged between 18 and 65 years.
- The Expanded Disability Status Scale (EDSS) score prior to the current disease episode is ≤ 4.
- Female participants of childbearing potential must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.
- Informed consent must be obtained from the patient or their legal representative, with a signed consent form must be provided.
Exclusion Criteria:
- Abnormal laboratory indicators of the subjects need to be excluded, including, but not limited to, the following indicators:
White blood cell count < 3 × 10⁹/L Neutrophil count < 1.5 × 10⁹/L Hemoglobin < 85 g/L Platelet count < 80 × 10⁹/L Serum creatinine > 1.5 × ULN Total bilirubin > 1.5 × ULN Aspartate aminotransferase (AST) > 3 × ULN Alanine aminotransferase (ALT) > 3 × ULN Alkaline phosphatase > 2 × ULN (AST = Aspartate Aminotransferase; GOT = Glutamic-Oxaloacetic Transaminase; ALT = Alanine Aminotransferase; GPT = Glutamic-Pyruvic Transaminase)
- Any contraindications to lumbar puncture.
- Pregnant or breastfeeding women, and patients with plans to conceive during the trial.
- Patients with a known history of allergies to human-derived biological products or those with an allergic predisposition.
- Patients who have undergone hematopoietic stem cell transplantation or lymphatic irradiation before enrollment.
- Patients who have participated in any other clinical trial within the last 3 months.
- Patients with severe comorbidities, including immunodeficiency or coagulation disorders.
- Patients with active suicidal ideation within 6 months before screening or have a history of suicide attempts within 3 years before screening.
- Patients with severe psychiatric symptoms that prevent clinical cooperation.
- Patients with positive for alcohol addiction or drug abuse.
- Patients with malignant tumors.
- Patients who have experienced any of the following events within 12 weeks before enrollment: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Class IV heart failure.
- Patients with persistent systemic infections and severe local infections.
- Patients unable to undergo magnetic resonance imaging during the trial.
- Patients deemed unsuitable for participation by the investigator.
Quoted from ClinicalTrials.gov, NCT06620809, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06620809, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.